Emergent Biosolutions

Emergent BioSolutions is a global specialty biopharmaceutical company dedicated to one simple mission—to protect and enhance life. We develop, manufacture, and deliver a portfolio of medical countermeasures for biological and chemical threats as well as emerging infectious diseases. We also develop and commercialize therapeutics and other specialty products for hospitals and clinics in the areas of hematology/oncology, transplantation, infectious diseases and autoimmune disorders. Through our work, we envision protecting and enhancing 50 million lives with our products by 2025.

Type
Public
HQ
Gaithersburg, US
Founded
1998
Employees
1,292 (est)
Emergent Biosolutions was founded in 1998 and is headquartered in Gaithersburg, US

Emergent Biosolutions Locations

Gaithersburg, US
Seattle, US
Singapore, SG
Richmond, GB
Gaithersburg, US
Baltimore, US
Baltimore, US
Winnipeg, CA
Lansing, US
Gaithersburg, US
Washington, US
Hattiesburg, US

Emergent Biosolutions Metrics

Emergent Biosolutions Summary

Market capitalization

$1.15 B

Closing share price

$28.3
Emergent Biosolutions's current market capitalization is $1.15 B.

Emergent Biosolutions Financials

Emergent Biosolutions's revenue is $523 M in FY, 2015 which is 67.16% increase from the previous period.
FY, 2013FY, 2015

Revenue

$313 M$523 M

Gross profit

$251 M$398 M

Operating income

$42.8 M$96 M

Net Income

$30.3 M$62.9 M

Operating cash flow

$37.7 M$32.3 M

    Emergent Biosolutions Market Value History

    Emergent Biosolutions Online Presence

    Emergent Biosolutions News

    Emergent Biosolutions Company Life

    You may also be interested in